A prp injection success rate cannot predict your result

A prp injection success rate describes a group

A clinic rate sounds firm, but first ask who was counted. Ask what level of relief counted as success and what treatment each person received. Without those facts, the rate says little about your likely result.

Rest, easier activity, and time can also ease an aching joint. A fair test compares PRP with another form of care. Even a careful comparison can't tell you exactly how you will feel.

Platelet count means the total in the treatment

A platelet count tells how many platelets are in all the liquid used. Concentration tells how tightly those platelets are packed into that liquid. A small jar can hold less rice than a large jar, even when packed tighter.

The same rule applies to concentrated PRP. A small liquid amount may have crowded platelets but fewer of them overall. Research hasn't found that each increase in the total brings more relief.

Your daily limits tell the clinic more than one rate

Before the appointment, note which tasks bring soreness and how long stiffness lasts. Take earlier scan pictures and a written record of every medicine you use. Your notes help the clinician focus the exam on your concern.

Until then, keep activity easy enough that the joint settles by the next day. Stop sooner if it becomes unsteady or the ache keeps rising. Tell the clinic what you hope to do more comfortably.

Sources

1. A systematic review and meta-analysis of platelet dosage across musculoskeletal conditions identified a potential dose-response relationship in knee osteoarthritis, with an apparent threshold above 10 billion platelets for favourable clinical outcomes, and the effect more pronounced for function than for pain. For conditions other than knee OA the authors found the literature too unclear to identify an optimal dose.

   Berrigan W, Tao F, Kopcow J, et al. — The Effect of Platelet Dose on Outcomes after Platelet Rich Plasma Injections for Musculoskeletal Conditions: A Systematic Review and Meta-Analysis. Current Reviews in Musculoskeletal Medicine, 2024. DOI: 10.1007/s12178-024-09922-x.

2. A systematic review of 29 randomized trials of PRP for knee OA that reported a platelet count, concentration or dose found that the 28 treatment arms with statistically significant positive outcomes at 6 months had a mean platelet dose of 5,500 (+/-474) x 10^6, while the three arms without a positive difference averaged 2,302 (+/-437) x 10^6 (P<.01). The same separation held at 12 months: 5,464 versus 2,253 x 10^6 (P<.05).

   Berrigan WA, Bailowitz Z, Park A, et al. — A Greater Platelet Dose May Yield Better Clinical Outcomes for Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review. Arthroscopy, 2025. DOI: 10.1016/j.arthro.2024.03.018.

3. A randomized study of 150 patients compared PRP standardised to an absolute count of 10 billion platelets against hyaluronic acid, following patients for one year. Adding a 1-micron filtration step raised platelet recovery to about 90%. WOMAC, IKDC and 6-minute pain-free walking distance were all significantly better in the PRP group at one year, and the authors concluded that an absolute count of 10 billion platelets is the critical variable for a sustained effect in moderate knee OA.

   Bansal H, Leon J, Pont JL, et al. — Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy. Scientific Reports, 2021. DOI: 10.1038/s41598-021-83025-2.

4. A prospective cohort of 253 patients with KL 1-3 knee OA treated with three injections of 5 mL of autologous PRP found that platelet concentration positively correlated with clinical outcome. KOOS Pain improved more with higher platelet concentration at 2 months (P=.036), 6 months (P=.009) and 12 months (P=.014), with the same trend across other KOOS subscales and IKDC. The failure rate was 15.0% in the low-platelet group versus 3.3% in both the medium- and high-platelet groups, with no difference in adverse events.

   Boffa A, De Marziani L, Andriolo L, et al. — Influence of Platelet Concentration on the Clinical Outcome of Platelet-Rich Plasma Injections in Knee Osteoarthritis. American Journal of Sports Medicine, 2024. DOI: 10.1177/03635465241283463.

5. A triple-blind randomized trial in 99 knees with early (KL 1-2) knee OA compared a conventional 4 mL PRP dose (mean 2.82 billion platelets) with an 8 mL 'superdose' (mean 5.65 billion), both leukocyte-depleted and prepared identically. Both groups improved on WOMAC, VAS and KOOS over six months. The trial is a direct demonstration that 'a PRP injection' is not one intervention: the same preparation at two volumes delivers a two-fold difference in platelet dose.

   Patel S, Gahlaut S, Thami T, et al. — Comparison of Conventional Dose Versus Superdose Platelet-Rich Plasma for Knee Osteoarthritis: A Prospective, Triple-Blind, Randomized Clinical Trial. Orthopaedic Journal of Sports Medicine, 2024. DOI: 10.1177/23259671241227863.

6. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA.

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.19415.